Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,472
datasets available to search
ShareScore release 0.9.0
Dataset results
1,472 results for “EGFR”
Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
ClinicalTrials.gov study NCT07398599. IPD Sharing: NO. Countries: 1. Publications: 0.
Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer
ClinicalTrials.gov study NCT03311750. IPD Sharing: Not stated. Countries: 2. Publications: 0.
The Detection of EGFR Mutations in Liquid Based Cytology Samples
ClinicalTrials.gov study NCT04086680. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients
ClinicalTrials.gov study NCT07363252. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC
ClinicalTrials.gov study NCT01528488. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR
ClinicalTrials.gov study NCT01744925. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Practical Usability of EGFR Mutation Detection in ctDNA From Resectable NSCLC
ClinicalTrials.gov study NCT04922073. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT04479306. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT03050411. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.
ClinicalTrials.gov study NCT05785208. IPD Sharing: NO. Countries: 1. Publications: 0.
Study on the Effectiveness of an Emollient Cream Containing Pre and Postbiotic and Niacinamide 4% in the Treatment of Skin Xerosis and Itching in Oncological Patients Treated with Anti-EGFR
ClinicalTrials.gov study NCT06868771. IPD Sharing: NO. Countries: 1. Publications: 0.
Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib:
ClinicalTrials.gov study NCT04517526. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study
ClinicalTrials.gov study NCT03410043. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT06268210. IPD Sharing: NO. Countries: 1. Publications: 0.
Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma
ClinicalTrials.gov study NCT04354961. IPD Sharing: NO. Countries: 1. Publications: 0.
Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy
ClinicalTrials.gov study NCT04508816. IPD Sharing: Not stated. Countries: 1. Publications: 0.
e- Ab Sensor-based Real-time Detection of Mutant EGFR in Clinical Specimens From Patients of Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT01359436. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM
ClinicalTrials.gov study NCT02766699. IPD Sharing: NO. Countries: 1. Publications: 0.
A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine
ClinicalTrials.gov study NCT04147351. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-ge
ClinicalTrials.gov study NCT06441045. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.